Joint Research Activities Sample Clauses

Joint Research Activities. The application portfolio is adapted to the MAPPERinfrastructure. Our approach is that applications are up and running from the start of the project, with existing, easily adaptable and deployable tools in the fast track; the deeper track then produces enhancements, which are fed into the user level fast track as and when ready. A number of programming and execution tools, dedicated to distributed multi-scale computing, are developed. In the first phase of the project, the applications will have to rely on explicit coding of their multi-scale simulations, but gradually programming tools are delivered that assist in this task. JRA tools allow interaction between software components from different e- infrastructures in a hybrid way. User communities: MAPPER is driven by seven exemplar applications from five user communities (virtual physiological human, computational biology, fusion, hydrological engineering, nano material science), and these communities are specifically targeted. However, our solutions are generic and will enable distributed multi-scale computing for any multi-scale model fitting into our paradigm, and MAPPER therefore opens up to other user communities as well.
Sample 1Sample 2Sample 3
AutoNDA by SimpleDocs
Joint Research Activities. Subject to the terms and conditions herein, during each applicable Joint Research Term, on a Collaboration Degrader Target Set-by-Collaboration Degrader Target Set basis, (a) the Parties will each use Commercially Reasonable Efforts to conduct the Research activities allocated to such Party in the applicable Joint Research Plan, and (b) without limiting the foregoing, Nurix will use Commercially Reasonable Efforts to (i) identify, synthesize, and characterize and deliver to Seagen Degraders that selectively bind and degrade one (1) or more of the Degrader Target(s) in the applicable Collaboration Degrader Target Set (including by conducting one (1) or more DEL Screens with respect to such Collaboration Degrader Target Set; provided, that if Nurix conducts any such DEL Screen(s) without Seagen’s prior written request, Nurix shall provide written notice to Seagen through the JRC that such DEL Screen(s) have been conducted, which notice shall summarize the results of such DEL Screen(s) in reasonable detail), (ii) optimize one (1) or more of the Degraders identified or synthesized through clause (i) above to cause pharmacologically relevant activity as a result of degrading one (1) or more of the Degrader Target(s) in such Collaboration Degrader Target Set, for the purpose of creating Collaboration Degraders that are Directed To such Collaboration Degrader Target Set; and (iii) work with Seagen to evaluate such Collaboration Degraders that are Directed To such Collaboration Degrader Target Set, including until they satisfy the applicable Collaboration Degrader Criteria, in each case (clauses (i)-(iii)), in accordance with the applicable Joint Research Plan (“Nurix Research”), and (c) once a Collaboration Degrader that is Directed To the applicable Collaboration Degrader Target Set satisfies the applicable Collaboration Degrader Criteria, Seagen will use Commercially Reasonable Efforts to (1) conjugate such Collaboration Degrader to one (1) or more Antibodies selected by Seagen, and (2) test whether the resulting Collaboration Degrader-Antibody Conjugates satisfy the applicable [*] Potency Benchmark, in each case, in accordance with the applicable Joint Research Plan (“Seagen Research”). For clarity, evaluation and optimization of a Collaboration Degrader may, in accordance with the applicable Joint Research Plan, continue after such Collaboration Degrader has satisfied the applicable Collaboration Degrader Criteria. Each Research Program will be subject to the...
Sample 1Sample 2
Joint Research Activities. The several JRAs in Opticon cover a wide range of challenges related to development of future astronomical instrumentation – the community contribution to E-ELT and next generation facilities, with complementary approaches including the range from technically challenging developments of systems, which are known to be on the critical path for next generation instrumentation, through investigations of new technologies of high potential impact but as-yet less certain practicality. The balance between these activities has been set in part by the development of the Opticon astronomical technology Roadmap, and in part by critical analysis of the very wide range of possible activities by the national funding agency scientific directors who make up the Opticon Executive Board. For clarity, we briefly consider each JRA area in turn. Adaptive Optics (WP1) Adaptive optics (AO) systems, using both natural and laser guide stars, are the key technologies for the next major advances in ground-based optical-IR astronomy in the next 20 years. Significant progress made over the past ten years in the field of AO has brought this observational technique to the maturity level where outstanding astronomical results can be obtained routinely. Astronomers are now looking toward the next generation of AO systems, which will allow them to extend this powerful technique to new observing modes. Previous Opticon activity aimed to design and develop Laser Guide Star Adaptive Optics systems for the existing large telescopes (Large Binocular Telescope, Very Large Telescope, Xxxxxxx Xxxxxxxx Xxxescope), to upgrade extent Adaptive Optics systems for the large Solar telescope (GREGOR solar telescope) and to upgrade the Very Large Telescope Planet Finder instrument (SPHERE) to maintain its competitiveness in the period 2012- 2014. The primary goal of this contract is to develop the technologies and the knowledge required to improve the performance and operational efficiency of these existing AO facilities in Europe, as well as to develop the state-of-the-art second generation instrumentation required for the 40m European Extremely Large Telescope (E-ELT). Fast Detectors (WP2) Opticon activity defines the state-of-the-art in this field. Outstanding performance was obtained from the Opticon developed camera Ocam and its dedicated detector, the CCD220 (which has led to commercial spinoffs – see below). Ocam technology is currently used by the second generation of VLT Adaptive Optics (AO) instru...
Sample 1
Joint Research Activities. Joint research is to be encouraged as individual scholars or departments establish contact and develop mutual interests. Furthermore, the respective universities support the exchange of research materials to enhance scientific research activities. The conditions of such agreements will be individually negotiated.
Sample 1
Joint Research Activities. MICROKELVIN has the following 4 Joint Research Activities: JRA1 Opening microkelvin regime to nanoscience JRA2 Ultralow temperature nanorefrigerator JRA3 Attacking fundamental physics questions by microkelvin condensed-matter experiments JRA4 Novel methods and devices for ultra low temperature measurements The MICROKELVIN Collaboration is building up access capacity by constructing in JRA1 three new microkelvin refrigerators, one on each access-giving site. These will be available for us- ers at the beginning of 2011. Two of them (AALTO and CNRS) will be pulsed-tube based nuclear demagnetization refrigerators, and commissioned for cooling nanosamples to ultralow temperatures. In addition of increasing the access capacity at AALTO and CNRS they will also reduce the time spent on a single experiment by more than factor of two. These two refrigerators will be the first He-free microkelvin refrigerators. These prototypes, if successful, will lead the rest of the ultra-low community to adopt this He-saving technology and secure its future beyond the depletion of He re- serves in 2030. In JRA2 the consortium is going to use nanotechnology for constructing beyond the-state- of-the-art microrefrigerators for cooling nanosamples to ultralow temperatures. Microrefrigeration is a relatively young invention from 1994. It utilizes the thermal current accompanying the electri- cal current, when it flows through a tunnelling barrier (similar to the Xxxxxxx effect). The cooling power of the microrefrigerators is small but well-suited to refrigerating nano-size samples. One can also easily mass-produce them for parallel operation. They have already been demonstrated to cool electrons (the coolant) from 300 mK to 50 mK and other nano-size samples from 300 mK to 200 mK. These numbers are still far away from the low temperature records of conventional large re- frigerators, which are 6 μK for bulk 3-dimensional electron samples and 4 mK for 2-dimensional electron gas in GaAs/AlGaAs heterostructures. The microrefrigerators are ideal for selfcooling their electron baths due to the poor thermal contact to the outside world via the phonon bath. In JRA2 the MICROKELVIN Collaboration will develop microrefrigerators for self-cooling their electron gas from 10 mK starting temperature to below 4 mK final temperature. At the same time the refrigera- tion of other nanosamples will be improved to 100 mK. In JRA3 the 3 access giving sites will jointly develop techniques for answering sele...
Sample 1
Joint Research Activities. The parties agree to collaborate in joint research activities, 87 subject to the availability of funds and other forms of support that may be required for 88 such activities; and subject to applicable laws, regulations and institutional policies. If 89 joint research activities are anticipated, separate agreement are required for joint 90 research activities. 91 92 D. Joint Faculty Appointments: When feasible and applicable, there may be mutual 93 recognition through appropriate appointment of faculty from either Affiliate or 94 (Institution) as part of joint research activities and scholarly exchanges. Such 95 appointments shall not carry any form of remuneration and shall be subject 96 to the appointment procedures of the institution for which such an appointment 97 without salary is sought.
Sample 1
Joint Research Activities. (JRA) to improve the scientific and technological standards of services provided by the consortium. VetBioNet brings together 27 partners from 12 different countries across Europe, Africa, and Oceania (France, Germany, The Netherlands, Denmark, United Kingdom, Spain, Italy, Switzerland, Poland, Ireland, Kenya and Australia). VetBioNet principal objectives are to reinforce the cooperation between Europe’s leading high- containment research infrastructures, to provide access to the high-containment research facilities of the network, and to further improve the technical standard of the services provided. Before the start of the ERG, the VetBioNet H2020 project has developed some assets that serve as a basis of the VetBioNet ERG. The VetBioNet H2020 project provided academic and private research communities with free-of- charge and easy access to BSL3 facilities and expertise to support zoonotic and epizootic research.The VetBioNet H2020 project also provided training and best practice guidelines for high-containment laboratory/animal facility experimentation and ethics, as well as new approaches to animal experimentation and alternative models to reduce animal use according to the principals of the 3Rs: replacement, reduction, and refinement. Research activities of the VetBioNet H2020 project have allowed the development and validation of new analytical tools, reagents and methods to help interrogate the host-pathogen interaction (immunogenetics, NanoString or Fludigm transcriptomics, diagnostic polyclonal and monoclonal antibodies to name just a few) and to study animal behavior in an infectious context (prototype of telemetric sensors and behavioral analysis software) as well as alternative in vitro models for infectious studies (cell lines, 3D cellular models). The VetBioNet H2020 project has produced: − Best practice guidelines for the management of biocontained animal facilities and laboratories and ethics for animal experimentation, available on the public e-learning platform on VetBioNet website. − Detailed protocols (culture, cell infection, establishment of alternative in vitro models, state-of-the-art approaches for imaging interactions between live pathogens and host cells) − Education and training dedicated to researchers or animal caretakers in different sectors, such as industry and academia (3Rs, Biorisk biosafety and Biosecurity management, analytical approaches for the study of host-pathogen interactions) − Databases (cellular and animal mod...
Sample 1
AutoNDA by SimpleDocs
Joint Research Activities 
Sample 1Sample 2Sample 3See All (4)

Related to Joint Research Activities

  • Development Activities The Development activities referred to in item “b” of paragraph 3.1 include: studies and projects of implementation of the Production facilities; drilling and completion of the Producing and injection xxxxx; and installation of equipment and vessels for extraction, collection, Treatment, storage, and transfer of Oil and Gas. The installation referred to in item “c” includes, but is not limited to, offshore platforms, pipelines, Oil and Gas Treatment plants, equipment and facilities for measurement of the inspected Production, wellhead equipment, production pipes, flow lines, tanks, and other facilities exclusively intended for extraction, as well as oil and gas pipelines for Production Outflow and their respective compressor and pumping stations.

  • Research Collaboration Upon FibroGen’s request, the Parties will discuss conducting a research program funded by AstraZeneca and directed toward franchise enhancement and lifecycle management for HIF Compounds or other topics that the Parties determine relevant to the Products and the Field. Upon agreement on the terms of such research program, the Parties will enter into a separate agreement or amend this Agreement accordingly.

  • Collaboration We believe joint effort toward common goals achieves trust and produces greater impact for L.A. County’s youngest children and their families.

  • Research Program 2.1 University will use reasonable efforts to conduct the Research Program described in Attachment A which is hereby incorporated in full by reference (“Research Program”), and will furnish the facilities necessary to carry out said Research Program. The Research Program will be under the direction of _____________________ (“Principal Investigator”), or his or her successor as mutually agreed to by the Parties and will be con­ducted by the Principal Investigator at the University.

  • Research Project 3.1 These Materials and Data will be used by Recipient's PI solely in connection with the Research Project, as named and described in the attached research application (insert Research Project name below):

  • Research Use The Requester agrees that if access is approved, (1) the PI named in the DAR and (2) those named in the “Senior/Key Person Profile” section of the DAR, including the Information Technology Director and any trainee, employee, or contractor1 working on the proposed research project under the direct oversight of these individuals, shall become Approved Users of the requested dataset(s). Research use will occur solely in connection with the approved research project described in the DAR, which includes a 1-2 paragraph description of the proposed research (i.e., a Research Use Statement). Investigators interested in using Cloud Computing for data storage and analysis must request permission to use Cloud Computing in the DAR and identify the Cloud Service Provider (CSP) or providers and/or Private Cloud System (PCS) that they propose to use. They must also submit a Cloud Computing Use Statement as part of the DAR that describes the type of service and how it will be used to carry out the proposed research as described in the Research Use Statement. If the Approved Users plan to collaborate with investigators outside the Requester, the investigators at each external site must submit an independent DAR using the same project title and Research Use Statement, and if using the cloud, Cloud Computing Use Statement. New uses of these data outside those described in the DAR will require submission of a new DAR; modifications to the research project will require submission of an amendment to this application (e.g., adding or deleting Requester Collaborators from the Requester, adding datasets to an approved project). Access to the requested dataset(s) is granted for a period of one (1) year, with the option to renew access or close-out a project at the end of that year. Submitting Investigator(s), or their collaborators, who provided the data or samples used to generate controlled-access datasets subject to the NIH GDS Policy and who have Institutional Review Board (IRB) approval and who meet any other study specific terms of access, are exempt from the limitation on the scope of the research use as defined in the DAR.

  • Development and Commercialization Subject to Sections 4.6 and 4.7, Fibrocell shall be solely responsible for the development and Commercialization of Fibrocell Products and Improved Products. Fibrocell shall be responsible for all costs incurred in connection with the Fibroblast Program except that Intrexon shall be responsible for the following: (a) costs of establishing manufacturing capabilities and facilities in connection with Intrexon’s manufacturing obligation under Section 4.6 (provided, however, that Intrexon may include an allocable portion of such costs, through depreciation and amortization, when calculating the Fully Loaded Cost of manufacturing a Fibrocell Product, to the extent such allocation, depreciation, and amortization is permitted by US GAAP, it being recognized that the majority of non-facilities scale-up costs cannot be capitalized and amortized under US GAAP); (b) costs of basic research with respect to the Intrexon Channel Technology and Intrexon Materials (i.e., platform improvements) but, for clarity, excluding research described in Section 4.7 or research requested by the JSC for the development of a Fibrocell Product or an Improved Product (which research costs shall be reimbursed by Fibrocell); (c) [*****]; and (d) costs of filing, prosecution and maintenance of Intrexon Patents. The costs encompassed within subsection (a) above shall include the scale-up of Intrexon Materials and related active pharmaceutical ingredients for clinical trials and Commercialization of Fibrocell Products undertaken pursuant to Section 4.6, which shall be at Intrexon’s cost whether it elects to conduct such efforts internally or through Third Party contractors retained by either Intrexon or Fibrocell (with Intrexon’s consent).

  • Research Plan The Parties recognize that the Research Plan describes the collaborative research and development activities they will undertake and that interim research goals set forth in the Research Plan are good faith guidelines. Should events occur that require modification of these goals, then by mutual agreement the Parties can modify them through an amendment, according to Paragraph 13.6.

  • Development Program A. Development activities to be undertaken (Please break activities into subunits with the date of completion of major milestones)

  • Research Matters By entering into this Agreement, the Placement Agent does not provide any promise, either explicitly or implicitly, of favorable or continued research coverage of the Company and the Company hereby acknowledges and agrees that the Placement Agent’s selection as a placement agent for the Offering was in no way conditioned, explicitly or implicitly, on the Placement Agent providing favorable or any research coverage of the Company. In accordance with FINRA Rule 2711(e), the parties acknowledge and agree that the Placement Agent has not directly or indirectly offered favorable research, a specific rating or a specific price target, or threatened to change research, a rating or a price target, to the Company or inducement for the receipt of business or compensation.

Time is Money Join Law Insider Premium to draft better contracts faster.